Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
Rhea-AI Summary
Protagonist Therapeutics (NASDAQ: PTGX) announced CEO Dinesh V. Patel will participate in multiple investment bank conferences in March 2026. Events include TD Cowen (Boston, Mar 2-4), Leerink (Miami, Mar 8-11), Jefferies and Citizens (Miami, Mar 10-11), and Barclays (Miami, Mar 10-12).
Live webcasts and replays will be available; investors can request meetings via conference representatives. Replays will be posted on the company's investor relations page for one year following each event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
PTGX was up 4.63% while momentum data flagged only ZLAB, which was moving down by 2.28%. Other close biotech peers showed mixed, smaller moves, supporting a stock-specific setup rather than a sector-wide trade.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Conference participation | Positive | +0.1% | J.P. Morgan Healthcare Conference presentation and investor meetings announcement. |
| Jan 05 | Regulatory milestone | Positive | -3.4% | NDA submission to FDA for rusfertide in adults with polycythemia vera. |
| Nov 06 | Earnings and update | Positive | -0.3% | Q3 2025 results with $678.8M cash and multiple late-stage program milestones. |
| Nov 03 | Clinical data update | Positive | +0.7% | Rusfertide VERIFY and THRIVE data presentations at the 67th ASH Meeting. |
| Oct 27 | Clinical data update | Positive | +0.5% | New icotrokinra data in ulcerative colitis and plaque psoriasis from October 2025. |
Positive regulatory/clinical and event-related headlines often saw modestly positive reactions, with occasional divergences on major milestones like the rusfertide NDA.
Over the last several months, Protagonist has reported multiple clinically and strategically significant updates. These include a New Drug Application for rusfertide in polycythemia vera (PV) on Jan 5, 2026, strong Q3 2025 cash of $678.8M supporting development through at least end of 2028, and new icotrokinra data with notable remission and response rates in ulcerative colitis and plaque psoriasis. Repeated conference and data presentations suggest an ongoing investor-relations and medical-outreach effort, into which the March 2026 conference slate neatly fits.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration dated 2025-08-06, expiring on 2028-08-06, with 0 recorded usages in the provided data. This indicates capacity for future registered offerings, though no specific amounts or takedowns are detailed here.
Market Pulse Summary
This announcement outlines an intensive conference schedule across multiple healthcare investor events in March 2026, emphasizing ongoing outreach to institutions and analysts. In recent months, Protagonist reported major milestones such as an NDA filing for rusfertide and strong icotrokinra data, alongside a solid cash position as of Q3 2025. Investors may watch for new data disclosures, partnership commentary, or strategic updates during these fireside chats and one-on-one meetings, as well as any follow-on corporate actions using existing registration capacity.
AI-generated analysis. Not financial advice.
NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in March 2026.
TD Cowen 46th Annual Health Care Conference; Boston, MA - March 2-4, 2026
Format: Fireside Chat
Day/Time: Tuesday, March 3 at 11:50 A.M. ET
Webcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/6QuKhqDYvNSrPH8co9v5gd
Leerink Global Healthcare Conference; Miami, FL - March 8-11, 2026
Format: Fireside Chat
Day/Time: Monday, March 9 at 4:20 P.M. ET
Webcast: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/K8FdPptAY5cyfndeY9RPP9
Jefferies Biotech on the Beach Summit; Miami, FL - March 10-11, 2026
Format: One-on-one Meetings
Day/Time: Tuesday, March 10
Citizens Life Sciences Conference; Miami, FL - March 10-11, 2026
Format: Fireside Chat
Day/Time: Wednesday, March 11 at 1:05 P.M. ET
Webcast: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/UWj58vHDxUk6PseGJr4ebs
Barclays 28th Annual Global Healthcare Conference; Miami, FL - March 10-12, 2026
Format: Fireside Chat
Day/Time: Thursday, March 12 at 11:30 A.M. ET
Webcast: https://cc.webcasts.com/barc002/031026a_js/?entity=30_ESKWJT8
If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.
A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
When will Protagonist Therapeutics (PTGX) present at the TD Cowen Health Care Conference in March 2026?
How can investors watch Protagonist Therapeutics (PTGX) events at Leerink Global Healthcare Conference on March 9, 2026?
Is Protagonist Therapeutics (PTGX) meeting investors at Jefferies Biotech on the Beach in March 2026?
When and where will Protagonist Therapeutics (PTGX) appear at the Citizens Life Sciences Conference in March 2026?
What is the schedule for Protagonist Therapeutics (PTGX) at the Barclays Global Healthcare Conference in March 2026?
How long will Protagonist Therapeutics (PTGX) webcasts and replays be available after the March 2026 conferences?
